Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status Prescription
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.052481%Not Available
Jaundice cholestatic09.01.01.0050.005831%Not Available
Joint effusion15.01.02.0050.005831%
Joint swelling15.01.02.004--Not Available
Ketonuria20.02.01.0090.008747%Not Available
Kidney infection20.01.09.004; 11.01.14.0060.029156%
Laboratory test abnormal13.18.01.001--Not Available
Labyrinthitis11.01.05.002; 04.04.03.0010.011662%Not Available
Laceration12.01.06.006; 23.03.11.004--Not Available
Lacrimation increased06.08.02.004--
Lactic acidosis14.01.01.002--Not Available
Laryngeal pain22.02.05.036--
Lenticular opacities06.06.01.003--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukaemia16.01.03.001; 01.10.03.0010.028142%
Leukocytosis01.02.01.0020.026240%
Leukopenia01.02.02.001--Not Available
Ligament sprain15.07.02.004; 12.01.07.0080.005831%Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.032071%Not Available
Lipase increased13.05.01.0030.011662%
Listless19.04.04.003; 08.01.01.0120.005831%Not Available
Liver abscess11.01.18.001; 09.01.11.0010.005831%Not Available
Liver disorder09.01.08.0010.104961%Not Available
Liver function test abnormal13.03.01.0130.061227%Not Available
Localised infection11.01.08.0060.023325%Not Available
Loss of consciousness17.02.04.004--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.0020.014578%Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphocyte count decreased13.01.06.006--
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 28 Pages